These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8458321)

  • 1. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation.
    Slingerland JM; Jenkins JR; Benchimol S
    EMBO J; 1993 Mar; 12(3):1029-37. PubMed ID: 8458321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concerted regulation of wild-type p53 nuclear accumulation and activation by S100B and calcium-dependent protein kinase C.
    Scotto C; Delphin C; Deloulme JC; Baudier J
    Mol Cell Biol; 1999 Oct; 19(10):7168-80. PubMed ID: 10490652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
    Raycroft L; Wu HY; Lozano G
    Science; 1990 Aug; 249(4972):1049-51. PubMed ID: 2144364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene.
    Felley-Bosco E; Weston A; Cawley HM; Bennett WP; Harris CC
    Am J Hum Genet; 1993 Sep; 53(3):752-9. PubMed ID: 8352280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why are there hotspot mutations in the TP53 gene in human cancers?
    Baugh EH; Ke H; Levine AJ; Bonneau RA; Chan CS
    Cell Death Differ; 2018 Jan; 25(1):154-160. PubMed ID: 29099487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A platform for interrogating cancer-associated p53 alleles.
    D'Brot A; Kurtz P; Regan E; Jakubowski B; Abrams JM
    Oncogene; 2017 Jan; 36(2):286-291. PubMed ID: 26996664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant.
    Humpton TJ; Hock AK; Maddocks ODK; Vousden KH
    Cancer Metab; 2018; 6():18. PubMed ID: 30524726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.
    Kim E; Ilic N; Shrestha Y; Zou L; Kamburov A; Zhu C; Yang X; Lubonja R; Tran N; Nguyen C; Lawrence MS; Piccioni F; Bagul M; Doench JG; Chouinard CR; Wu X; Hogstrom L; Natoli T; Tamayo P; Horn H; Corsello SM; Lage K; Root DE; Subramanian A; Golub TR; Getz G; Boehm JS; Hahn WC
    Cancer Discov; 2016 Jul; 6(7):714-26. PubMed ID: 27147599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of full-length p53 aggregates and their kinetics of formation.
    Julian L; Sang JC; Wu Y; Meisl G; Brelstaff JH; Miller A; Cheetham MR; Vendruscolo M; Knowles TPJ; Ruggeri FS; Bryant C; Ros S; Brindle KM; Klenerman D
    Biophys J; 2022 Nov; 121(22):4280-4298. PubMed ID: 36230002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53: Multiple Facets of a Rubik's Cube.
    Zhang Y; Lozano G
    Annu Rev Cancer Biol; 2017 Mar; 1():185-201. PubMed ID: 30775651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tale of two alleles: TP53 and transformation in MPNs.
    Brierley C; Psaila B
    Blood; 2022 Jun; 139(25):3567-3568. PubMed ID: 35737408
    [No Abstract]   [Full Text] [Related]  

  • 12. p53 tetramerization: at the center of the dominant-negative effect of mutant p53.
    Gencel-Augusto J; Lozano G
    Genes Dev; 2020 Sep; 34(17-18):1128-1146. PubMed ID: 32873579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 suppresses CCL2-induced subcutaneous tumor xenograft.
    Tang X; Amar S
    Tumour Biol; 2015 Apr; 36(4):2801-8. PubMed ID: 25492482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 is an important regulator of CCL2 gene expression.
    Tang X; Asano M; O'Reilly A; Farquhar A; Yang Y; Amar S
    Curr Mol Med; 2012 Sep; 12(8):929-43. PubMed ID: 22804246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.
    Humar M; Maurer M; Azemar M; Groner B
    J Cancer Res Clin Oncol; 2009 Apr; 135(4):567-80. PubMed ID: 18846387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex.
    Querido E; Morrison MR; Chu-Pham-Dang H; Thirlwell SW; Boivin D; Branton PE
    J Virol; 2001 Jan; 75(2):699-709. PubMed ID: 11134283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meanfield approach to the thermodynamics of a protein-solvent system with application to the oligomerization of the tumor suppressor p53.
    Noolandi J; Davison TS; Volkel AR; Nie X; Kay C; Arrowsmith CH
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):9955-60. PubMed ID: 10944184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High metastatic potential in mice inheriting a targeted p53 missense mutation.
    Liu G; McDonnell TJ; Montes de Oca Luna R; Kapoor M; Mims B; El-Naggar AK; Lozano G
    Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4174-9. PubMed ID: 10760284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in levels of normal ML-1 gene transcripts associated with the conversion of human nontumorigenic to tumorigenic phenotypes.
    Sun XL; Li D; Fang J; Noyes I; Casto B; Theil K; Shuler C; Milo GE
    Gene Expr; 1999; 8(2):129-39. PubMed ID: 10551800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different regulation of the p53 core domain activities 3'-to-5' exonuclease and sequence-specific DNA binding.
    Janus F; Albrechtsen N; Knippschild U; Wiesmüller L; Grosse F; Deppert W
    Mol Cell Biol; 1999 Mar; 19(3):2155-68. PubMed ID: 10022902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.